The inductive mechanisms of PD-L1 protein abundance in RCC cells by miR-224-5p may provide a molecular basis for the development of miR-224-5p as a promising non-invasive biomarker for immunotherapies in RCC treatment. Here, CD274 is linked to renal cell carcinoma.